ITI Pharma and Healthcare Fund Direct Growth

ITI Pharma and Healthcare Fund Direct Growth

Equity

Direct

Sector - Healthcare

NAV as on 22-11-2024

₹ 17.81

1.4%

1D

Inception Returns

21%

/yr

About ITI Pharma and Healthcare Fund Direct Growth

ITI Pharma and Healthcare Fund Direct Growth is an equity fund. This fund was started on 11 November, 2021. The fund is managed by . The fund could potentially beat inflation in the long-run.

Key Parameters

  1. ITI Pharma and Healthcare Fund Direct Growth has ₹208 Cr worth of assets under management (AUM) as on Oct 2024 and is less than category average.
  2. The fund has an expense ratio 0.5.

Returns

ITI Pharma and Healthcare Fund Direct Growth has given a CAGR return of 20.96% since inception. Over the last 1 and 3 years the fund has given a CAGR return of 46.92% and 21.61% respectively.

Holdings

ITI Pharma and Healthcare Fund Direct Growth has allocated its funds majorly in Cash Equivalent, Health, Basic Materials, Financial Services. Its top holdings are Sun Pharmaceuticals Industries Ltd, Lupin Ltd, Suven Pharmaceuticals Ltd, Apollo Hospitals Enterprise Ltd, Divi's Laboratories Ltd

Taxation

As it is a sector - healthcare mutual fund the taxation is as follows:
For short term (less than a year) capital gains will be taxed at 15%
For long term (more than 1 year) capital gains will be taxed at 10% without indexation benefit
Dividends will always be taxed at slab rate. Gains upto Rs 1 lakh are exempt in case of long term.

Investment objective of ITI Pharma and Healthcare Fund Direct Growth

The investment objective of the scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies engaged in Pharma and Healthcare. However, there can be no assurance that the investment objective of the scheme would be achieved.

Minimum Investment and lockin period

Minimum investment for lump sum payment is INR 5000.00 and for SIP is INR 500.00. ITI Pharma and Healthcare Fund Direct Growth has no lock in period.

Historical NAV & Returns

Annualised

zero opening, trading, fund transfer fee
120 people have invested ₹ 6.8L in ITI Pharma and Healthcare Fund Direct Growth in the last three months

ITI Pharma and Healthcare Fund Direct Growth Overview

Expense ratio0.47%
Benchmark
S&P BSE Healthcare PR
AUM₹208 Cr
Inception Date11 November, 2021
Min Lumpsum/SIP₹5000/₹500
Exit Load
1.0%
Lock InNo Lock-in
TurnOver
61.96%
STCGRedeeming before 1 year, returns taxed at 20%.
LTCGAfter 1 year, 12.5% tax on returns over ₹1.25 lakh/year.
Risk
Risk meter
pointer
Very High Risk

Trailing Returns

as on (22-Nov-24)

Period
ITI Pharma and Healthcare Fund Direct Growth
Nifty 500
sector - healthcare
1M
1.6%
-2.6%
-3.9%
3M
3.6%
-5.2%
-0.6%
6M
23.8%
4.7%
17.4%
1Y
46.9%
26.1%
40.4%
3Y
21.6%
14.1%
18.7%

Fund Distribution

as on (31-Oct-24)

  • Equity 98.2%

  • Debt & Cash 1.8%

Large cap
38.1%

Small cap
31.5%

Mid cap
26.4%

Sector Allocation

Oct'24

Sep'24

Aug'24

Health
96.7%
Basic Materials
2%
Financial Services
1.2%
All changes are between Aug'24 and Oct'24
Oct'24
Sep'24
Aug'24
Fund Returns
0.46%
2.61%
5.97%
Nifty 500
-6.52%
2.04%
0.97%
  • This fund’s returns stands at 0.46% whereas the fund’s underlying benchmark Nifty 500 returns stands at -6.52% as on Oct'24
  • This fund outperformed Nifty 500 by 6.97% in Oct'24
Parameters
Oct'24
Sep'24
Aug'24
AUM
₹ 208.2 Cr
₹ 201.9 Cr
₹ 194.8 Cr
  • AUM of the fund stands at 208.2 Cr as of Oct'24
  • AUM increased by 6.3 Cr between Oct'24 and Sep'24
Top Stocks bought last month
Divi's Laboratories Ltd's allocation increased from 3% to 4.76%
Divi's Laboratories Ltd's allocation increased from 3% to 4.76%
Strides Pharma Science Ltd's allocation increased from 1.03% to 1.91%
Strides Pharma Science Ltd's allocation increased from 1.03% to 1.91%
Suven Pharmaceuticals Ltd's allocation increased from 5.58% to 6.06%
Suven Pharmaceuticals Ltd's allocation increased from 5.58% to 6.06%
Top Stocks sold last month
Sun Pharmaceuticals Industries Ltd's allocation decreased from 16.25 % to 15.6 %
Sun Pharmaceuticals Industries Ltd's allocation decreased from 16.25 % to 15.6 %
Lupin Ltd's allocation decreased from 6.79 % to 6.72 %
Lupin Ltd's allocation decreased from 6.79 % to 6.72 %
Apollo Hospitals Enterprise Ltd's allocation decreased from 5.57 % to 5.42 %
Apollo Hospitals Enterprise Ltd's allocation decreased from 5.57 % to 5.42 %
Mid Cap allocation has gone up from 26.1% to 26.4%
Mid Cap allocation has gone up from 26.1% to 26.4%
Large Cap allocation has gone down from 38.5% to 38.1%
Large Cap allocation has gone down from 38.5% to 38.1%
Small Cap allocation has gone up from 30.7% to 31.5%
Small Cap allocation has gone up from 30.7% to 31.5%
Cash allocation has gone down from 3.6% to 1.8%
Cash allocation has gone down from 3.6% to 1.8%

Top 3 Sectors in October were Health, Basic Materials & Financial Services

Oct'24
Health
97%
Basic Materials
2%
Financial Services
1%
Sep'24
Health
97%
Basic Materials
3%
  • Gainers

  • Losers

Fund
Oct'24
Sep'24
Aug'24
No of Holdings
40
39
39
Top 5 Company Concentration
38.6%
39.2%
39%
Company having highest exposure
Sun Pharmaceuticals Industries Ltd (15.6%)
Sun Pharmaceuticals Industries Ltd (16.3%)
Sun Pharmaceuticals Industries Ltd (15.9%)
No of Sectors
3
2
2
Top 5 Sectors Concentration
100%
100%
100%
Sector having highest exposure
Health (96.7%)
Health (97.2%)
Health (97.2%)
Loading...
We are taking more time than usual
Fund House
ITI Asset Management Limited
Total Schemes
Total AUM
₹9.95K Cr
as on 31-Oct-2024
Address
Naman Midtown “A” Wing, 21st Floor, Senapati Bapat Marg, Elphinstone Road
Phone
022-66214999
Website
mfassist@itiorg.com

ITI Pharma and Healthcare Fund Direct Growth Highlights

Risk meter
pointer

Very High Risk

Investors understand that their principal will be at Very High Risk
About the fund

About the fund

This fund has delivered an average annual returns of 20.96% since inception which is less than its category average return of 24.93%
Fund Allocations

Fund Allocations

This fund has an allocation of 98.2% in Equity, 0% in Debt and 1.8% in Cash related instruments
AUM size ₹208 Cr

AUM size ₹208 Cr

This fund has AUM of ₹208 Cr which is less than its category average of ₹ 2001 Cr
Expense Ratio 0.47%

Expense Ratio 0.47%

This fund has an expense ratio of 0.47% which is less than its category average expense ratio of 1.33%

Frequently Asked Questions for ITI Pharma and Healthcare Fund Direct Growth

The current NAV of ITI Pharma and Healthcare Fund Direct Growth is ₹17.81 as on 22-Nov-2024.
Existing (Absolute + CAGR) as on 22-Nov-2024.
ITI Pharma and Healthcare Fund Direct Growth
Absolute Returns
CAGR Returns
1 Month Returns
1.56%
1.56%
6 Month Returns
23.84%
23.84%
1 Year Returns
46.92%
46.92%
3 Years Returns
79.83%
21.61%
5 Years Returns
0%
0%
With INDmoney, the process of investing is very simple and involves zero commission.
  • Click Buy on the fund name.
  • Input the amount you are looking to invest.
  • Select Lump Sum or SIP (Weekly, Monthly or Quarterly).
  • Select your bank account and proceed with Payment.
0.47% as on October 2024
₹208 Cr as on October 2024
Sun Pharmaceuticals Industries Ltd(15.6%), Lupin Ltd(6.72%), Suven Pharmaceuticals Ltd(6.06%), Apollo Hospitals Enterprise Ltd(5.42%), Divi's Laboratories Ltd(4.76%) as on October 2024
Health(94.99%), Basic Materials(2%), Financial Services(1.21%) as on October 2024
The alpha ratio for the ITI Pharma and Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Alpha 1 Year
Alpha 3 Years
Alpha 5 Years
ITI Pharma and Healthcare Fund Direct Growth
7.72
-
-
As on October 2024
The alpha for ITI Pharma and Healthcare Fund Direct Growth is calculated against S&P BSE Healthcare PR. Higher alpha indicates that this fund has generated extra returns compared to the benchmark index. An alpha of 1.0 means the fund has outperformed its benchmark index by 1%.
The Beta ratio for the ITI Pharma and Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Beta 1 Year
Beta 3 Years
Beta 5 Years
ITI Pharma and Healthcare Fund Direct Growth
0.89
-
-
As on October 2024
The Beta for ITI Pharma and Healthcare Fund Direct Growth is calculated with S&P BSE Healthcare PR. Beta tells the volatility of the mutual fund relative to its benchmark. If the beta of a mutual fund is more than 1, then the mutual fund is more volatile than its benchmark. If beta is less than 1, then the mutual fund is less volatile than the benchmark.
The sharpe ratio for the ITI Pharma and Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Sharpe Ratio 1 Year
Sharpe Ratio 3 Years
Sharpe Ratio 5 Years
ITI Pharma and Healthcare Fund Direct Growth
3.06
-
-
As on October 2024
The sharpe ratio for ITI Pharma and Healthcare Fund Direct Growth is calculated with S&P BSE Healthcare PR. Sharpe ratio tells risk-adjusted-returns of the mutual fund. The higher a fund's Sharpe ratio, the better a fund's returns have been relative to the risk it has taken on.
The standard deviation for the ITI Pharma and Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Standard Deviation 1 Year
Standard Deviation 3 Years
Standard Deviation 5 Years
ITI Pharma and Healthcare Fund Direct Growth
14.16
-
-
As on October 2024
Standard deviation tells the volatility of the returns of the mutual fund. The higher a fund's Standard deviation, the higher the volatility of the fund's returns.
The Exit load of ITI Pharma and Healthcare Fund Direct Growth is 1%